SOUTH SAN FRANCISCO, Calif. and
PARSIPPANY, N.J., July 7, 2020 /PRNewswire/ -- Trianni, Inc.
(TRIANNI) and Zoetis (NYSE: ZTS) today announced a collaboration
for the development of transgenic monoclonal antibody platforms for
the discovery of new veterinary treatments.
"We are confident that the application of TRIANNI's proven
transgenic human monoclonal antibody discovery platform technology
to the veterinary field will add value to Zoetis' product
development programs," said Matthias Wabl, Ph.D., Trianni's
President and CEO.
"We appreciate TRIANNI's experience in the development of
therapeutic antibody platform capabilities and look forward to
working with them on innovations for animal health," said
Catherine A. Knupp, D.V.M., M.S.,
Executive Vice President and President, Research and Development at
Zoetis. "This collaboration will enhance our internally-developed
pipeline of novel monoclonal antibodies and hasten the development
of therapeutics that could transform the way veterinarians treat a
range of diseases in animals."
No financial details were disclosed.
About Trianni, Inc.
Trianni, Inc. is a privately held
biotech company specializing in antibody discovery technology.
TRIANNI's lead technology, The Trianni Mouse®, is a
next-generation platform enabling efficient generation of
fully-human monoclonal antibodies. TRIANNI's transgenic
platform leverages a novel approach to design made possible by
advances in DNA synthesis and genomic modification technology,
making it a best-in-class therapeutic antibody discovery platform.
The company is headquartered in San
Francisco, CA. Additional information about TRIANNI is
available through its corporate website, www.trianni.com.
About Zoetis
Zoetis is the leading animal health
company, dedicated to supporting its customers and their
businesses. Building on more than 65 years of experience in animal
health, Zoetis discovers, develops, manufactures and commercializes
medicines, vaccines and diagnostic products, which are complemented
by biodevices, genetic tests and precision livestock farming.
Zoetis serves veterinarians, livestock producers and people who
raise and care for farm and companion animals with sales of its
products in more than 100 countries. In 2019, the company generated
annual revenue of $6.3 billion with
approximately 10,600 employees. For more information, visit
www.zoetis.com.
Forward-looking Information
This press release contains forward-looking statements, which
reflect the current views of Zoetis with respect to business plans
or prospects, expectations regarding products, the development of
future products and other future events. These statements are not
guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more
of these risks or uncertainties materialize, or if management's
underlying assumptions prove to be incorrect, actual results may
differ materially from those contemplated by a forward-looking
statement. Forward-looking statements speak only as of the date on
which they are made. Zoetis expressly disclaims any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can be found
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2019, including in the
sections thereof captioned "Forward-Looking Statements and Factors
That May Affect Future Results" and "Item 1A. Risk Factors," in our
Quarterly Reports on Form 10-Q and in our Current Reports on Form
8-K. These filings and subsequent filings are available online at
www.sec.gov, www.zoetis.com, or on request from Zoetis.
Media Contact: Trianni, Inc.
Elizabeth Tran
Marketing Manager
elizabeth.tran@trianni.com
(415) 231-0257
Media Contact: Zoetis
Christina Lood
christina.lood@zoetis.com
(973) 822-7249
View original content to download
multimedia:http://www.prnewswire.com/news-releases/trianni-and-zoetis-announce-agreement-to-develop-a-transgenic-antibody-discovery-platform-for-use-in-animal-health-301088673.html
SOURCE Trianni